NewsBenzingaEnlivex、Phase 2bのAllocetra膝変形性関節症試験を優先するためのコスト削減計画を開始、トップラインデータは2027年半ばまでに予定 Enlivex、Phase 2bのAllocetra膝変形性関節症試験を優先するためのコスト削減計画を開始、トップラインデータは2027年半ばまでに予定 Benzinga 2026.10.19 12:20 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
